医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Kona Medical Closes $10 Million Financing

2013年10月21日 PM09:25
このエントリーをはてなブックマークに追加


 

BELLEVUE, Wash. & MENLO PARK, Calif.

Kona Medical, Inc. (www.konamedical.com) today announced it has closed a Series D equity financing of $10 million. Morningside Group, a broad-based investment firm with significant presence in China, led the investment and is the sole investor. “These funds are earmarked for the China market,” said Michael Gertner, MD, founder and CEO of Kona Medical. “Our research predicts a very large market in China for a non-invasive therapy to treat hypertension. This investment will allow Kona to begin navigating the complex clinical, regulatory, and intellectual property issues associated with this region. We are very pleased to have an experienced investor in the region join the Kona syndicate.”

“Kona Medical has tremendous potential,” said Reenie McCarthy for Morningside. “We look forward to working with the company to bring this important therapy to market.”

About Kona Medical

Kona Medical’s Surround Sound® Renal Denervation System utilizes ultrasound, delivered from outside the body, to treat nerves leading to and from the kidney. Renal denervation has been shown in clinical studies to lead to significant and lasting reductions in blood pressure in drug-resistant hypertension patients. Kona’s non-invasive system offers the opportunity to increase patient access to renal denervation and lower healthcare costs. Kona is based in Bellevue, Washington, and Menlo Park, California.

For additional information, please visit www.konamedical.com.

About Morningside

Morningside is a diversified investment group founded in 1986 and engaged primarily in private equity and venture capital investments. The group has investments in North America, Europe, and across Asia-Pacific. Morningside is an active investor in early-stage life science companies formed around new technologies which represent a high degree of novelty over existing technologies. More information is available at www.morningside.com.

Note: Kona Medical’s technology is investigational and is not yet for sale or approved by the US Food and Drug Administration.

CONTACT

Kona Medical, Inc.
John Bowers, 425-558-4616
Chief Operating
Officer
jbowers@konamedical.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • SpeeDxが迅速なポイントオブケア診断法を開発するためにCARB-Xから資金提供を受ける
  • UPL、東南アジアでのフルピリミン・ライスの独占入手でMeijiとの協業を発表
  • UPL宣布与明治医药合作,在东南亚地区独家供应水稻杀虫剂Flupyrimin产品
  • Genetron Health Announces Strategic Partnership with Siemens Healthineers to Promote Precision Oncology for Lung Cancer
  • MagBio Genomics Inc.面向Mawi iSWAB-RNA v2开发用于Thermofisher KingFisher™ Flex的自动化RNA纯化方法